Relfydess
Relfydess is Galderma’s relabotulinumtoxinA product, a botulinum toxin type A product developed, manufactured, and commercialized within Galderma. It is separate from Dysport: Dysport is an Ipsen-origin abobotulinumtoxinA product for which Galderma holds aesthetic commercialization rights in licensed territories.
Galderma describes Relfydess as a ready-to-use liquid product that does not require reconstitution. That presentation detail does not make it interchangeable with other toxin products or establish a clinical advantage over a lyophilized product.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Relfydess |
| Nonproprietary name | RelabotulinumtoxinA |
| Toxin type | Botulinum toxin type A |
| Developer | Galderma |
| Manufacturer | Galderma (Galderma product profile 🔗) |
| Commercialization | Galderma in approved markets |
| Presentation context | Ready-to-use liquid product; no reconstitution described by Galderma |
| Regulatory distinction | Approved internationally; not documented here as FDA approved in the United States |
International And U.S. Status
Section titled “International And U.S. Status”On July 1, 2026, Galderma stated that Relfydess was approved in 33 markets and launched in more than 20, including markets in Europe, the United Kingdom, the Middle East, Asia, and Australia. Approvals, indications, vial presentations, and product information remain market-specific.
The same announcement reported that FDA had issued a Complete Response Letter for relabotulinumtoxinA in the United States. Galderma described the comments as relating to observations during a manufacturing-site inspection and analytical-method optimization. A CRL is not approval, so Relfydess should not be presented as FDA approved or available in the United States on the basis of its international approvals.
Dysport And Relfydess Are Different Relationships
Section titled “Dysport And Relfydess Are Different Relationships”| Product | Product-origin and company relationship | Why the distinction matters |
|---|---|---|
| Dysport | Ipsen-origin abobotulinumtoxinA; Galderma commercializes aesthetic Dysport in licensed territories. | Commercialization rights do not make Dysport a Galderma-developed product. |
| Relfydess | Galderma-developed relabotulinumtoxinA product. | Its approvals, formulation, units, and regulatory record must be read separately from Dysport. |
Comparison Limits
Section titled “Comparison Limits”Relfydess shares type A biology with Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Letybo, but it does not share a universal unit scale, label, or evidence base with them. A ready-to-use liquid presentation also does not support a general claim about safety, diffusion, onset, duration, or superiority.
Graph Connections
Section titled “Graph Connections”Galderma connects two distinct toxin roles: licensed aesthetic commercialization for Dysport and the developer-manufacturer role for Relfydess. Flemming Ørnskov provides Galderma’s current public-company context. Botulinum toxin type A explains the shared serotype without flattening product differences.